Takeda infectious news
Takeda will launch its vaccine business division on Jan. 1 to develop Takeda's pediatric vaccine products, including Haemophilus influenzae type B ( Hib) vaccine TAK-816, and TAK-361S, a quadrivalent vaccine for diphtheria, pertussis, tetanus and polio. The division will seek to in-license additional products. Concurrently, Takeda will pursue alliances to expand its vaccine business worldwide. The company believes that its September acquisition of Nycomed will support these efforts, given Nycomed's "strong business infrastructure in Europe and emerging markets" (see BioCentury, Oct. 3).
Takeda hired Rajeev Venkayya as head of the vaccine division, effective Jan. 15. Venkayya is the director of vaccine delivery at the Bill & Melinda Gates Foundation. ...